My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

1.160 -0.020 (-1.69%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about MIRA Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study ↗

May 06, 2025

Ketamir-2 from MIRA Pharmaceuticals showed no brain toxicity in rats, meeting FDA study requirements and advancing its clinical development program.

Via Benzinga

On Wednesday, there are stocks with unusual volume. Let's take a look. ↗

April 23, 2025

These stocks have an unusual volume in today's session

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 17, 2025

Via Benzinga

Is Mira Pharmaceuticals Gaining or Losing Market Support? ↗

April 17, 2025

Via Benzinga

Mira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical Trial ↗

April 16, 2025

The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects.

Via Stocktwits

Peering Into Mira Pharmaceuticals's Recent Short Interest ↗

September 11, 2024

Via Benzinga

(MIRA) - Analyzing Mira Pharmaceuticals's Short Interest ↗

July 26, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 16, 2025

Via Benzinga

Which stocks are gapping on Wednesday? ↗

April 16, 2025

The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 16, 2025

Via Benzinga

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study ↗

April 16, 2025

MIRA's Ketamir-2 shows promise in treating diabetic neuropathy, with a Phase 2a trial expected by late 2025 and human data in early 2026.

Via Benzinga

EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug ↗

March 24, 2025

MIRA Pharmaceuticals signs letter of intent to acquire SKNY Pharmaceuticals, adding SKNY-1, a preclinical drug for weight loss and smoking cessation, to its portfolio.

Via Benzinga

EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate ↗

March 13, 2025

MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical studies are advancing this year.

Via Benzinga

EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain ↗

March 04, 2025

MIRA Pharmaceuticals gains approval for a Phase 1 trial of Ketamir-2 in Israel, aiming to complete by Q4 2025 before moving to Phase 2a in neuropathic pain.

Via Benzinga

EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment ↗

December 19, 2024

MIRA Pharmaceuticals submits an IND for Ketamir-2, aiming to treat neuropathic pain with 100% pain reversal shown in preclinical studies.

Via Benzinga

EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain ↗

December 10, 2024

MIRA Pharmaceuticals completes preclinical safety studies for Ketamir-2, confirming no adverse findings as it targets an Investigational New Drug submission by late 2024.

Via Benzinga

MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain ↗

October 28, 2024

MIRA Pharmaceuticals stock rises as new preclinical data reveal its oral ketamine analog Ketamir-2 is 60% more effective than gabapentin in pain relief.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 25, 2024

Via Benzinga

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

October 03, 2024

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Via News Direct

Topics Cannabis

Why Mira Shares Are Trading Higher Today ↗

September 27, 2024

MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) shares are trading higher Friday following the announcement of promising new preclinical data for its lead development product, Ketamir-2. Here's what you need...

Via Benzinga

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

September 19, 2024

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

Via News Direct

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

August 27, 2024

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Via News Direct

MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies ↗

August 26, 2024

MIRA Pharmaceuticals stock surges on promising preclinical results of oral ketamine analog, Ketamir-2, showing 100% pain threshold normalization in rats, positioning it as a potential breakthrough for...

Via Benzinga

Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket ↗

August 26, 2024

Via Benzinga

Heico, PDD Holdings And 3 Stocks To Watch Heading Into Monday ↗

August 26, 2024

Via Benzinga

MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024 ↗

August 13, 2024

MIRA stock results show that Mira Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

August 05, 2024

Via Benzinga

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank? ↗

August 01, 2024

A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here's a look at the others.

Via Benzinga

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

July 29, 2024

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Via News Direct

Topics Cannabis

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.